USFDA approves Bristol Myers and 2seventy bio’s Abecma for triple-class exposed multiple myeloma
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
The company plans to add 1700 beds by FY27 through the organic route
TriClip offers a remarkably safe, minimally invasive treatment option for patients in need of tricuspid valve repair but who are unable to withstand surgery
Reconfirms a relative bioavailability of 65 percent and significant savings when using DL-methionine
Aurigene.AI is an end-to-end solution for small molecule drug discovery
New leadership team announced at NATHEALTH Annual General Meeting 2024
This is the fourth authorized indication in Europe for Reblozyl, a first-in-class treatment for patients with disease-related anemia
Usnoflast (ZYIL1) is a novel oral small molecule NLRP3 inhibitor discovered at Zydus
Subscribe To Our Newsletter & Stay Updated